Russell Investments Group Ltd. Has $64.44 Million Stock Holdings in Zoetis Inc. $ZTS

Russell Investments Group Ltd. raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 54.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 893,500 shares of the company’s stock after acquiring an additional 314,747 shares during the period. Russell Investments Group Ltd. owned approximately 0.21% of Zoetis worth $64,441,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. University of Texas Texas AM Investment Management Co. bought a new position in shares of Zoetis in the 2nd quarter worth $25,000. Prosperity Bancshares Inc bought a new stake in Zoetis in the fourth quarter valued at about $25,000. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis in the first quarter valued at about $28,000. Root Financial Partners LLC lifted its stake in Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares during the period. Finally, Elyxium Wealth LLC bought a new position in Zoetis during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ZTS shares. Barclays decreased their target price on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Argus reiterated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. William Blair reissued a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, Zacks Research downgraded shares of Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $109.62.

Zoetis Stock Down 2.9%

NYSE:ZTS opened at $73.64 on Friday. Zoetis Inc. has a 1 year low of $71.45 and a 1 year high of $160.48. The stock has a 50-day moving average price of $76.30 and a two-hundred day moving average price of $99.01. The stock has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a PEG ratio of 1.28 and a beta of 0.74. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the firm earned $1.76 EPS. Zoetis’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 34.93%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.